# Shanghai Lianhe Investment

> Shanghai Lianhe Investment is a VC fund in Shanghai backing Medical and Biopharma. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 8
- Last investment: Jan 2025
- Lead investor: 38%
- Last updated: Aug 2026
- Website: https://cn-sail.com/

Shanghai Lianhe Investment is a venture capital firm that focuses on biopharmaceutical, fintech, new energy, new materials, and more.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 25% |
| Biopharma | 2 | 25% |
| Biotechnology | 2 | 25% |
| Pharmaceutical | 2 | 25% |
| Fuel | 1 | 13% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Seed | 2 | 25% |
| Series B | 2 | 25% |
| Venture - Series Unknown | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Puxi Crystal | Pu Enjing engaged in the independent research and development of high-end polymer materials. |  | Series B | Jan 22, 2025 |  |
| ICT Developer | ICT Developer is a domestic green and sustainable fuel company. |  | Series A | Dec 30, 2024 |  |
| Sichuan Jiuyiyuan Particle Technology | Sichuan Jiuyiyuan Particle Technology Co., Ltd. was established in February 2017. It is a key demonstration high-tech enterprise of China Academy of Engineering Physics in response to the national strategy of military-civilian integration, developing military-civilian, high-end medical equipment, and biopharmaceuticals. The company is amixed-ownership enterprise jointly held by the Chinese Academy of Physics, the private sector, the R&D team, and SDIC Ventures. Relying on the core technology of accelerators, the company has gradually expanded to the development of various types of high-precision diagnostic equipment for nuclear medicine. The successfully developed medical cyclotron fills the gap in the country and will complete the first installation in 2019, achieving a breakthrough in commercialization. |  | Venture - Series Unknown | Sep 12, 2024 |  |
| Innostellar Biotherapeutics | Innostellar Biotherapeutics is a biopharmaceutical startup that focuses on gene therapy for novel medication research, manufacturing, and commercialization.Innostellar Biotherapeutics core team includes scientists and specialists from prestigious institutions and laboratories, as well as senior executives from leading biopharmaceutical firms. |  | Series B | Jun 11, 2024 |  |
| Jusheng Technology | Jusheng Technology is a graphical ASIC developer that primarily specializes in integrated circuit chip design and services, integrated circuit chip and product sales, information system integration services, and other related industries. |  | Seed | Mar 19, 2024 |  |
| Yuanxin Satellite | Yuanxin Satellite is a provider of low-orbit broadband multimedia satellite network operation services. The company integrates advanced technologies at home and abroad, and focuses on investment in the satellite industry and low-orbit broadband satellite networks. Yuanxin Satellite was founded on March 8 and is headquartered in Shanghai, China. | $943.5M | Series A | Feb 01, 2024 |  |
| Weiyan Medical | Micro Rock Medical is a biopharma and medical firm that focuses on precise molecular diagnosis for infections. | $15.7M | Series A | Nov 29, 2021 |  |
| InnoStar Semiconductor | InnoStar is a semiconductor storage maker producing storage products in the fields of information security protection, IoT, AI, and cloud. | $100M | Seed | Apr 06, 2021 |  |

8 of 8 investments shown.

## Co-investors
- [CAS Star](https://shizune.co/investors/profile/cas-star) — VC Fund, 2 deals together
- [New Alliance Capital](https://shizune.co/investors/profile/new-alliance-capital) — VC Fund, 2 deals together
- [AsiaInfo Security](https://shizune.co/investors/profile/asiainfo-security) — VC Fund, 1 deal together
- [Atlas Capital](https://shizune.co/investors/profile/atlas-capital) — VC Fund, 1 deal together
- [Atlas Capital](https://shizune.co/investors/profile/atlas-capital-3eb0) — VC Fund, 1 deal together
- [CAS Investment Management](https://shizune.co/investors/profile/cas-investment-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Shanghai Lianhe Investment invest in?

Shanghai Lianhe Investment invests primarily in Medical, Biopharma and Biotechnology startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shanghai Lianhe Investment last invest?

The most recent investment recorded for Shanghai Lianhe Investment closed in Jan 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co